Sofinnova'speople
Individual strengths, united purpose
We embrace individual uniqueness and diversity, while our greatest strength is in our unity and common purpose.
Antoine Papiernik
Chairman & Managing Partner, Sofinnova Partners
Henrijette Richter
Managing Partner, Sofinnova Partners
Graziano Seghezzi
Managing Partner, Sofinnova Partners
Alexandra Abreu
Analyst, Sofinnova Partners – Crossover Strategy
Joe Anderson
Partner, Sofinnova Partners - Crossover Strategy
Guillaume Baxter
Partner, Sofinnova Partners - Industrial Biotech Strategy
Anna Belousova
Associate, Sofinnova Partners - Industrial Biotech Strategy
Maina Bhaman
Partner, Sofinnova Partners - Capital Strategy
Joško Bobanović
Partner, Sofinnova Partners - Industrial Biotech Strategy
Gabriella Camboni
Partner, Sofinnova Partners - Biovelocita Strategy
Claire Catherinet
Senior Associate, Sofinnova Partners - Crossover Strategy
Mariam Cherifi
Associate, Sofinnova Partners - Industrial Biotech Strategy
Matthieu Coutet
Partner, Sofinnova Partners - Biovelocita Strategy
Cécile Dupont
Partner, Sofinnova Partners - MD Start Strategy
Marie Duranteau
Associate, Program Manager, Sofinnova Partners - Biovelocita Strategy
Lucia Faccio
Partner, Sofinnova Partners - Telethon Strategy
Marion Gasperment
Principal, Program Manager, Sofinnova Partners - MD Start Strategy
Aseem Ghaghda
Senior Associate, Sofinnova Partners - Capital Strategy
Anta Gkelou
Partner, Sofinnova Partners - Capital Strategy
Kinam Hong
Partner, Sofinnova Partners - Crossover Strategy
Mano Iyer
Partner, Sofinnova Partners - MD Start Strategy
Ankeet Jethwa
Senior Associate, Sofinnova Partners - Capital Strategy
Edward Kliphuis
Partner, Sofinnova Partners - Digital Medicine Strategy
Michael Krel
Partner, Sofinnova Partners - Industrial Biotech Strategy
Alex Leech
Partner, Sofinnova Partners - Biovelocita Strategy
Mary McCarthy
Partner, Sofinnova Partners - Industrial Biotech Strategy
Cedric Moreau
Partner, Sofinnova Partners - Crossover Strategy
Karl Naegler
Partner, Sofinnova Partners – Capital Strategy
Javier Nunez-Vicandi
Principal, Sofinnova Partners - Digital Medicine Strategy
Anne Osdoit
Partner, Sofinnova Partners - MD Start Strategy
Aishwarya Parthasarathy
Associate, Sofinnova Partners - Digital Medicine Strategy
Cristina Pelizon
Senior Associate, Program Manager, Sofinnova Partners - Biovelocita Strategy
Paola Pozzi
Partner, Sofinnova Partners - Telethon Strategy
Elliott Puttock
Analyst, Sofinnova Partners – Crossover Strategy
Tiziana Rossetti
Principal, Sofinnova Partners - Telethon Strategy
Gabriela Sachet Fernandez
Analyst, Sofinnova Partners - Industrial Biotech Strategy
Daniel Sieiro
Associate, Sofinnova Partners - Capital Strategy
Jacques Theurillat
Partner, Sofinnova Partners - Crossover Strategy
Simon Turner
Partner, Sofinnova Partners - Digital Medicine Strategy
Antonin Weckel
Analyst, Sofinnova Partners – Capital Strategy
Zhizhong Joel Yao
Partner, Sofinnova Partners - Biovelocita Strategy
Anis Belmili
Fund Accountant, Sofinnova Partners
Thomas Bermudes
Senior Legal Counsel, Sofinnova Partners
Christophe Blanche
Chief Financial Officer, Sofinnova Partners
Armance Bordes
General Counsel, Sofinnova Partners
Anne-Sophie Castaigne
Head of Operations and Projects Office, Sofinnova Partners
Gabriel Challot
Communications Designer, Sofinnova Partners
Sylvie Chapoy
Executive Assistant, Sofinnova Partners
Eugénie Cotte
Analyst, Sofinnova Partners
Laura Daudin-Antoine
Legal Counsel, Sofinnova Partners
Sandy Diep
Accountant at Sofinnova Partners
Matthieu Dreno
Senior Fund Accountant, Sofinnova Partners
Bertrand Echalard
Management Company Accounting, Sofinnova Partners
Martina Epi
Office Assistant at Sofinnova Partners
Lisa Flynn
Executive Assistant / Office Manager at Sofinnova Partners
Hortense Fouilland
Legal Counsel, Sofinnova Partners
Ahmed Fourati
Investor Relations and Reporting Officer, Sofinnova Partners
Juliette Grant
Executive Assistant, Sofinnova Partners
Johanna Guacide
Funds Accounting Manager, Sofinnova Partners
Stéphanie Huiban
Head of Information Systems, Sofinnova Partners
Paul Kilpatrick
Executive Assistant, Sofinnova Partners
Sarah Lafaye
ESG and Impact Officer, Sofinnova Partners
Marc Lahoudie
IT Systems & Application Support Administrator, Sofinnova Partners
Sandrine Le Penru
Executive Assistant, Sofinnova Partners
Aziliz Le Roux
Investor Relations, Sofinnova Partners
Bommy Lee
Head of Communications, Sofinnova Partners
Nathalie Loreaux
Investor Relations and Reporting Manager, Sofinnova Partners
Julia Metzger
Executive Assistant, Sofinnova Partners
Patrick S. Monnier
Senior Associate, Sofinnova Partners - Investor Relations
Caroline Patard
Administrative and Financial Manager, Sofinnova Partners
Agnès Pauquet
Head of Human Resources
Héloïse Percheron
Senior HR Officer, Sofinnova Partners
Enzo Petrelluzzi
Project Manager, Sofinnova Partners
Paola Pizzi
Head of Operations, Italy, Sofinnova Partners
Pamela Putz
Events and Community Manager, Sofinnova Partners
Ashvin Rajee
Paralegal, Sofinnova Partners
Estelle Rigaux
Head of Compliance, Sofinnova Partners
Pauline Roca
Office Manager, Sofinnova Partners
Sara Saoud
Investor Relations Analyst, Sofinnova Partners
Monique Saulnier
Senior Advisor, Sofinnova Partners
Karine Smolovic
Compliance Officer, Sofinnova Partners
Perrine Soupault
Senior Legal Counsel, Sofinnova Partners
Nicolas Tuvi
Analyst, Sofinnova Partners
Ligia Vela-Reid
Communication Manager, Sofinnova Partners
Lamia Verney
Executive Assistant, Sofinnova Partners
Gérard Hascoët
Venture Partner, Sofinnova Partners - MD Start Strategy
Josh Makower, MD
Venture Partner, Sofinnova Partners
Silvano Spinelli
Venture Partner, Sofinnova Partners
Martin T. Rothman
Venture Partner, Sofinnova Partners
Andrew M. Weiss
Venture Partner, Sofinnova Partners
Latest news
NodThera’s oral NLRP3 inhibitor NT-0796 enhances and sustains weight loss in combination with GLP-1
The Phase 3 ABTECT trials in patients with moderately to severely active Ulcerative Colitis
Rasmus Holm-Jorgensen appointed CFO at AAVantgarde
Mainstay Medical announces exclusive coverage of ReActiv8® by Anthem Blue Cross/Blue Shield
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)